Clinical Trial Detail

NCT ID NCT02644369
Title Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto
Indications

triple-receptor negative breast cancer

head and neck squamous cell carcinoma

Advanced Solid Tumor

melanoma

ovary epithelial cancer

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.